The PROMETHEUS feasibility trial enrolls 20 middle-aged-to-older adults in an 8-week multimodal intervention stratified by individual 'gerotypes' — biological aging patterns independent of chronological age. Core supplementation includes whey protein, creatine, and fucoidan for all participants, while urolithin A, nicotinamide mononucleotide (NMN), and/or multivitamin-multimineral are layered in based on baseline muscle mass, VO2peak, and cognitive performance. Mid-trial dose escalation or ergothioneine addition is triggered by inadequate cognitive response. Primary endpoints span muscle strength, immune function, and cognition; secondary outcomes include digital and molecular aging biomarkers.
What makes PROMETHEUS notable is its embedded adaptive logic — treating each participant as a dynamic system rather than a static trial unit. Most nutraceutical trials apply uniform dosing; this protocol operationalizes biological individuality as a treatment variable. The gerotype framework echoes emerging 'ageotype' research from the Snyder lab at Stanford, but extends it into an intervention-response model. That said, with only 20 participants and no control arm, this is explicitly a feasibility and signal-detection exercise, not an efficacy study. The compound stack — NMN, urolithin A, ergothioneine, creatine, fucoidan — represents some of the most compelling longevity nutraceutical candidates in current literature, though their synergistic effects remain poorly characterized. The design's real value lies in shaping a subsequent 12-month RCT. Incremental now, but architecturally significant if the personalization framework validates.
